Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
Saved in:
| Title: | Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3). |
|---|---|
| Authors: | Atsumi T; Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapporo, Japan., Tanaka Y; The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan., Matsubara T; Department of Orthopedics, Matsubara Mayflower Hospital, 944-25 Fujita, Kato, Japan., Amano K; Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Hidaka, Japan., Ishiguro N, Sugiyama E; Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan., Yamaoka K; Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan., Westhovens R; Department of Development and Regeneration, Skeletal Biology and Engineering Research Centre, Division of Rheumatology, University Hospitals KU Leuven, Leuven, Belgium., Ching DWT; Timaru Medical Specialists Limited, South Canterbury, New Zealand., Messina OD; Investigaciones Reumatologicas y Osteologicas SRL IRO, Buenos Aires, Argentina., Burmester GR; Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Free University and Humboldt University, Berlin, Germany., Bartok B; Gilead Sciences Inc., Foster City, CA, USA., Pechonkina A; Gilead Sciences Inc., Foster City, CA, USA., Kondo A; Gilead Sciences K.K., Tokyo, Japan., Yin Z; Gilead Sciences Inc., Foster City, CA, USA., Guo Y; Gilead Sciences Inc., Foster City, CA, USA., Tasset C; Galapagos NV, Mechelen, Belgium., Sundy JS; Gilead Sciences Inc., Foster City, CA, USA.; Department of Medicine, Duke University Medical Center, Durham, NC, USA.; Aichi Developmental Disability Center, Kasugai, Japan., Takeuchi T; Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan. |
| Source: | Modern rheumatology [Mod Rheumatol] 2022 Feb 28; Vol. 32 (2), pp. 273-283. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial |
| Journal Info: | Publisher: Oxford University Press Country of Publication: England NLM ID: 100959226 Publication Model: Print Cited Medium: Internet ISSN: 1439-7609 (Electronic) Linking ISSN: 14397595 NLM ISO Abbreviation: Mod Rheumatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1439-7609 |
|---|---|
| DOI: | 10.1093/mr/roab021 |
